EZH2: Difference between revisions

Search
PMC	articles
PubMed	articles
NCBI	proteins

Histone-lysine N-methyltransferase
Identifiers
EC number	2.1.1.43
Databases
IntEnz	IntEnz view
BRENDA	BRENDA entry
ExPASy	NiceZyme view
KEGG	KEGG entry
MetaCyc	metabolic pathway
PRIAM	profile
PDB structures	RCSB PDB PDBe PDBsum
Search
PMC	articles
PubMed	articles
NCBI	proteins

VALUE_ERROR (nil)
Identifiers
Aliases
External IDs	GeneCards: [1]
Orthologs
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	n/a
	Wikidata
View/Edit Human

VisualWikitext

Revision as of 17:02, 27 November 2017

Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme (EC 2.1.1.43) encoded by EZH2 gene, that participates in histone methylation and, ultimately, transcriptional repression.^[1] EZH2 catalyzes the addition of methyl groups to histone H3 at lysine 27,^[2] by using the cofactor S-adenosyl-L-methionine. Methylation activity of EZH2 facilitates heterochromatin formation thereby silences gene function.^[1] Remodeling of chromosomal heterochromatin by EZH2 is also required during cell mitosis.

EZH2 is the functional enzymatic component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for healthy embryonic development through the epigenetic maintenance of genes responsible for regulating development and differentiation.^[3] EZH2 is responsible for the methylation activity of PRC2, and the complex also contains proteins required for optimal function (EED, SUZ12, JARID2, AEBP2, RbAp46/48, and PCL).^[4]

Mutation or over-expression of EZH2 has been linked to many forms of cancer.^[5] EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is upregulated in multiple cancers including, but not limited to, breast,^[6] prostate,^[7] melanoma,^[8] and bladder cancer.^[9] Mutations in the EZH2 gene are also associated with Weaver syndrome, a rare congenital disorder,^[10] and EZH2 is involved in causing neurodegenerative symptoms in the nervous system disorder, ataxia telangiectasia.^[11]

Function

EZH2 is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2).^[12] EZH2's catalytic activity relies on its formation of a complex with at least two other PRC2 components, SUZ12 and EED.^[13]

As a histone methyltransferase (HMTase), EZH2's primary function is to methylate Lys-27 on histone 3 (H3K27me) by transferring a methyl group from the cofactor S-adenosyl-L-methionine (SAM). EZH2 is capable of mono-, di-, and tri-methylation of H3K27 and has been associated with a variety of biological functions, including transcriptional regulation in hematopoiesis, development, and cell differentiation.^[13]^[14]^[15]^[16]

Recent studies have indicated that EZH2 is also capable of methylating non-histone proteins.^[13]^[14]

Transcription repression

EZH2, as a part of PRC2, catalyzes trimethylation of H3K27 (H3K27me3), which is a histone modification that has been characterized as part of the histone code.^[12]^[16]^[17]^[18] The histone code is the theory that chemical modifications, such as methylation, acetylation, and ubiquitination, of histone proteins play distinctive roles in epigenetic regulation of gene transcription. EZH2-mediated catalysis of H3K27me3 is associated with long term transcription repression.^[12]^[16]^[17]

EZH2, as well as other Polycomb group proteins, are involved in establishing and maintaining gene repression through cell division.^[13]^[16] This transcriptionally repressive state is thought to be due to PRC2/EZH2-EED-mediated H3K27 methylation and subsequent recruitment of PRC1 which facilitates condensation of chromatin and formation of heterochromatin.^[16] Heterochromatin is tightly packed chromatin which limits the accessibility of transcription machinery to the underlying DNA, thereby suppressing transcription.^[19]

During cell division, heterochromatin formation is required for proper chromosome segregation.^[20] PRC2/EED-EZH2 complex may also be involved in the recruitment of DNA methyltransferases (DNMTs), which results in increased DNA methylation, another epigenetic layer of transcription repression.^[12]^[13] Specific genes that have been identified as targets of EZH2-mediated transcriptional repression include HOXA9, HOXC8, MYT1, CDKN2A and retinoic acid target genes.^[12]

Transcription activation

In cancer, EZH2 may play a role in activation of transcription, independently of PRC2.^[13] In breast cancer cells, EZH2 has been demonstrated to activate NF-κB target genes, which are involved in responses to stimuli.^[13] The functional role of this activity and its mechanism are still unknown.

Development and cell differentiation

EZH2 plays an essential role in development. In particular, it helps control transcriptional repression of genes that regulate cell differentiation.^[13]^[14]^[16]^[17] In embryonic stem cells, EZH2-mediated trimethylation of H3K27me3 in regions containing developmental genes appears to be important for maintenance of normal cell differentiation.^[16] H3K27me3 is also important in driving X-inactivation, the silencing of one X-chromosome in females during development.^[18] During X-inactivation, it is thought that EZH2 is involved in initiating heterochromatin formation by trimethylating H3K27 and that other histone methyltransferases and histone marks may be involved in maintaining the silenced state.^[21]

Further, EZH2 has been identified as an essential protein involved in development and differentiation of B-cells and T-cells.^[14] H3K27me3 is involved in suppressing genes that promote differentiation, thus maintaining an undifferentiated state of B- and T-cells and playing an important role in regulating hematopoiesis.^[14]

Regulation of EZH2 activity

The activity of EZH2 is regulated by the post-translational phosphorylation of threonine and serine residues on EZH2.^[22] Specifically, phosphorylation of T350 has been linked to an increase in EZH2 activity while phosphorylation of T492 and S21 have been linked to a decrease in EZH2 activity.^[17]^[22] Phosphorylation of T492 has been suggested to disrupt contacts between human EZH2 and its binding partners in the PRC2 complex, thus hindering its catalytic activity.^[17]

In addition to phosphorylation, it has also been shown that PRC2/EZH2-EED activity is antagonized by transcription-activating histone marks, such as acetylation of H3K27 (H3K27ac) and methylation of H3K36 (H3K36me).^[17]^[23]

Enzymatic activity

EZH2 function is highly dependent upon its recruitment by the PRC2 complex. In particular, WD40-repeat protein embryonic ectoderm development (EED) and zinc finger protein suppressor of zeste 12 (SUZ12) are needed to stabilize the interaction of EZH2 with its histone substrate^[24]^[25] Recently, two isoforms of EZH2 generated from alternative splicing have been identified in humans: EZH2α and EZH2β.^[26] Both isoforms contain elements that have been identified as important for EZH2 function including the nuclear localization signal, the EED and SUZ12 binding sites as well as the conserved SET domain.^[26] Most studies have thus far focused on the longer isoform EZH2α, but EZH2β, which lacks exons 4 and 8, has been shown to be active.^[26] Furthermore, PRC2/EZH2β complexes act on distinct genes from that of its PRC2/EZH2α counterpart suggesting that each isoform may act to regulate a specific subset of genes.^[26] Additional evidence suggests that EZH2 may also be capable of lysine methylation independent of association with PRC2, when EZH2 is highly upregulated.^[13]

Lysine methylation

File:Lysgen.pdf

Lysine can be methylated up to three times on its terminal ammonium group.

Methylation is the addition of a -CH₃, or methyl group, to another molecule. In biology, methylation is typically catalyzed by enzymes, and methyl groups are commonly added to either proteins or nucleic acids. In EZH2-catalyzed methylation, the amino acid lysine in the histone h3 is methylated. This amino acid residue can be methylated up to three times on its terminal ammonium group. These methylated lysines are important in the control of mammalian gene expression and have a functional role in heterochromatin formation, X-chromosome inactivation and transcriptional regulation.^[27] In mammalian chromosomes, histone lysine methylation can either activate or repress genes depending the site of methylation. Recent work has shown that at least part of the silencing function of the EZH2 complex is the methylation of histone H3 on lysine 27.^[28] Methylation, and other modifications, take place on the histones. Methyl modifications can affect the binding of proteins to these histones and either activate or inhibit transcription.^[20]

Mechanism of catalysis

File:EZH2 SET-domain.tiff

STAMP Alignment of EZH2 (Yellow; PDB: 4MI0) and Human SET7/9 (Cyan; PDB:1O9S) SET Domains with SAM (red) and Lysine (blue) bound.

EZH2 is a member of the SET domain family of lysine methyltransferases which function to add methyl groups to lysine side chains of substrate proteins.^[29] SET methyltransferases depend on a S-Adenosyl methionine (SAM) cofactor to act as a methyl donor for their catalytic activity. SET domain proteins differ from other SAM-dependent methyltransferases in that they bind their substrate and SAM cofactor on opposite sides of the active site of the enzyme. This orientation of substrate and cofactor allows SAM to dissociate without disrupting substrate binding and can lead to multiple rounds of lysine methylation without substrate dissociation.^[29]

Although neither a substrate-bound or SAM-bound crystal structure for EZH2 has been determined, STAMP structure alignment with the human SET7/9 methyltransferase shows conserved tyrosine residues in almost identical positions within the putative active site of EZH2.

File:EZH2 active site residues.tiff

STAMP Alignment of EZH2 (Yellow; PDB: 4MI0) and Human SET7/9 (Cyan; PDB:1O9S) Active Site Residues

It had been previously suggested that tyrosine 726 in the EZH2 active site was acting as a general base to de-protonate the substrate lysine but kinetic isotope effects have indicated that active site residues are not directly involved in the chemistry of the methyltransferase reaction.^[30] Instead these experiments support a mechanism in which the residues lower the pKa of the substrate lysine residue while simultaneously providing a channel for water to access the lysine side chain within the interior of the active site. Bulk solvent water can then easily deprotonate the lysine side chain, activating it for nucleophilic attack of the SAM cofactor in an S_N2-like reaction resulting in transfer of the methyl group from SAM to the lysine side chain.^[30]

File:Lysine Methylation by SAM.tif

Putative Catalytic Mechanism for EZH2

EZH2 primarily catalyzes mono- and di-methylation of H3K27 but a clinically relevant mutation of residue tyrosine 641 to phenylalanine (Y641F) results in higher H3K27 tri-methylation activity.^[30] It is proposed that the removal of the hydroxyl group on Y641 abrogates steric hindrance and allows for accommodation of a third methyl group on the substrate lysine. This EZH2 Y641F mutant is associated with many cancer phenotypes and implies that Y641 may be involved in regulating the number of methyl groups added to a single lysine residue.^[30]

Clinical significance

Cancer

EZH2 is an attractive target for anti-cancer therapy because it helps cancerous cells divide and proliferate. It is found in larger amounts than in healthy cells in a wide range of cancers including breast, prostate, bladder, uterine, and renal cancers, as well as melanoma and lymphoma. EZH2 is a gene suppressor, so when it becomes overexpressed, many tumor suppressor genes that are normally turned on, are turned off. Inhibition of EZH2 function shrinks malignant tumors in some reported cases because those tumor suppressor genes are not silenced by EZH2.^[31] EZH2 typically is not expressed in healthy adults; it is only found in actively dividing cells, like those active during fetal development.^[32] Because of this characteristic, overexpression of EZH2 can be used as a diagnostic marker of cancer and some neurodegenerative disorders.^[11] However, there are cases where it is difficult to tell whether overexpression of EZH2 is the cause of a disease, or simply a consequence. If it is only a consequence, targeting EZH2 for inhibition may not cure the disease. One example of a cancer pathway in which EZH2 plays a role is the pRB-E2F pathway. It is downstream from the pRB-E2F pathway, and signals from this pathway lead to EZH2 overexpression.^[33] Another important characteristic of EZH2 is that when EZH2 is overexpressed, it can activate genes without forming PRC2. This is an issue because it means the methylation activity of the enzyme is not mediated by complex formation. In breast cancer cells, EZH2 activates genes that promote cell proliferation and survival.^[13] It can also activate regulatory genes like c-myc and cyclin D1 by interacting with Wnt signaling factors.^[34] Importantly, the mutation of tyrosine 641 to phenylalanine in the active SET domain of EZH2 results in preference for H3K27 tri-methylation and has been linked to lymphoma.^[35]

File:EZH2 mechanism.pdf

Schematic depicting the effects of overexpression of EZH2 and mutation of EZH2 on transcription.

EZH2 Inhibitors

EZH2 Inhibitors.^a;^[36] ^b;^[37] ^c;^[38] ^d;^[39] ^e;^[32] ^f^[40]

Inhibitors

Developing an inhibitor of EZH2 and preventing unwanted histone methylation of tumor suppressor genes is a viable area of cancer research. EZH2 inhibitor development has focused on targeting the SET domain active site of the protein. Several inhibitors of EZH2 have been developed as of 2015, including 3-deazaneplanocin A (DZNep), EPZ005687, EI1, GSK126, and UNC1999. DZNep has potential antiviral and anti-cancer properties because it lowers EZH2 levels and induces apoptosis in breast and colon cancer cells.^[36] DZNep inhibits the hydrolysis of S-adenosyl-L-homocysteine (SAH), which is a product-based inhibitor of all protein methyltransferases, leading to increased cellular concentrations of SAH which in turn inhibits EZH2. However, DZNep is not specific to EZH2 and also inhibits other DNA methyltransferases.

In 2012, a company called Epizyme revealed EPZ005687, an S-adenosylmethionine (SAM) competitive inhibitor that is more selective than DZNep; it has a 50-fold increase in selectivity for EZH2 compared to EZH1. The drug blocks EZH2 activity by binding to the SET domain active site of the enzyme. EPZ005687 can also inhibit the Y641 and A677 mutants of EZH2, which may be applicable for treating non-Hodgkin's lymphoma.^[37] In 2013, Epizyme began Phase I clinical trials with another EZH2 inhibitor, tazemetostat (EPZ-6438), for patients with B-cell lymphoma.^[41]

Sinefungin is another SAM-competitive inhibitor, however, like DZNep, it is not specific to EZH2.^[40] It works by binding in the cofactor binding pocket of DNA methyltransferases to block methyl transfer. EI1 is another inhibitor, developed by Novartis, that showed EZH2 inhibitory activity in lymphoma tumor cells, including cells with the Y641 mutation.^[38] The mechanism of this inhibitor also involves competing with the SAM cofactor for binding to EZH2.^[38] GSK126 is a potent, SAM-competitive EZH2 inhibitor developed by GlaxoSmithKline, that has 150-fold selectivity over EZH1 and a K_i of 0.5-3 nM.^[39] UNC1999 was developed as an analogue of GSK126, and was the first orally bioavailable EZH2 inhibitor to show activity. However, it is less selective than its counterpart GSK126, and it binds to EZH1 as well, increasing the potential for off-target effects.

Combination therapies are being studied as possible treatments when primary treatments begin to fail. Etoposide, a topoisomerase inhibitor, when combined with an EZH2 inhibitor, becomes more effective for non-small cell lung cancers with BRG1 and EGFR mutations.^[31] However, EZH2 and lysine methylation can have tumor suppressing activity, for example in myelodysplastic syndrome,^[42] indicating that EZH2 inhibition may not be beneficial in all cases.

Weaver Syndrome

Mutations in the EZH2 gene have been linked with Weaver syndrome, a rare disorder characterized by advanced bone age, macrocephaly, and hypertelorism.^[10] The histidine residue in the active site of the wild-type EZH2 was mutated to tyrosine in patients diagnosed with Weaver syndrome.^[10] The mutation likely interferes with cofactor binding and causes disruption of the natural function of the protein.^[10]

Taxonomic distribution

File:EZH2 Gene Tree.png

frame

Enhancer of zeste (E(z)) was originally identified in Drosophila melanogaster, and its mammalian homologs were subsequently identified and named EZH1 (enhancer of zeste homolog 1) and EZH2 (enhancer of zeste homolog 2).^[44] EZH2 is highly conserved through evolution. It and its homologs play essential roles in development, cell differentiation, and cell division in plants, insects, fish, and mammals.^[13]^[17]^[45]^[46] The following taxonomic tree is a depiction of EZH2's distribution throughout a wide variety of species.^[47]^[48]

References

↑ ^1.0 ^1.1 Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. (2006). "The Polycomb group protein EZH2 directly controls DNA methylation". Nature. 439 (7078): 871–4. doi:10.1038/nature04431. PMID 16357870.
↑ Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y (2002). "Role of histone H3 lysine 27 methylation in Polycomb-group silencing". Science. 298 (5595): 1039–43. doi:10.1126/science.1076997. PMID 12351676.
↑ Morey L, Helin K (2010). "Polycomb group protein-mediated repression of transcription". Trends Biochem. Sci. 35 (6): 323–32. doi:10.1016/j.tibs.2010.02.009. PMID 20346678.
↑ Margueron R, Reinberg D (2011). "The Polycomb complex PRC2 and its mark in life". Nature. 469 (7330): 343–9. doi:10.1038/nature09784. PMC 3760771. PMID 21248841.
↑ Kim, Kimberly; Roberts, Charles (18 December 2015). "Targeting EZH2 in cancer". Nature Medicine. 22: 128–134. doi:10.1038/nm.4036. Retrieved 15 February 2016.
↑ Yoo KH, Hennighausen L (2012). "EZH2 methyltransferase and H3K27 methylation in breast cancer". Int. J. Biol. Sci. 8 (1): 59–65. doi:10.7150/ijbs.8.59. PMC 3226033. PMID 22211105.
↑ Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002). "The polycomb group protein EZH2 is involved in progression of prostate cancer". Nature. 419 (6907): 624–9. doi:10.1038/nature01075. PMID 12374981. Lay summary – Scientific American.
↑ Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, et al. (2015). "The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors". Nat Commun. 6: 6051. doi:10.1038/ncomms7051. PMID 25609585. Lay summary – MedicalResearch.com.
↑ Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caşkurlu T, Cakir OO, Ergenekon E (2005). "Increased expression of EZH2, a polycomb group protein, in bladder carcinoma". Urol. Int. 75 (3): 252–7. doi:10.1159/000087804. PMID 16215315.
↑ ^10.0 ^10.1 ^10.2 ^10.3 Gibson WT, Hood RL, Zhan SH, Bulman DE, Fejes AP, Moore R, et al. (2012). "Mutations in EZH2 cause Weaver syndrome". Am. J. Hum. Genet. 90 (1): 110–8. doi:10.1016/j.ajhg.2011.11.018. PMC 3257956. PMID 22177091.
↑ ^11.0 ^11.1 Li J, Hart RP, Mallimo EM, Swerdel MR, Kusnecov AW, Herrup K (2013). "EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia". Nat. Neurosci. 16 (12): 1745–53. doi:10.1038/nn.3564. PMC 3965909. PMID 24162653.
↑ ^12.0 ^12.1 ^12.2 ^12.3 ^12.4 Universal protein resource accession number Q15910 at UniProt.
↑ ^13.00 ^13.01 ^13.02 ^13.03 ^13.04 ^13.05 ^13.06 ^13.07 ^13.08 ^13.09 ^13.10 Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE (2014). "EZH2: biology, disease, and structure-based drug discovery". Acta Pharmacol. Sin. 35 (2): 161–74. doi:10.1038/aps.2013.161. PMC 3914023. PMID 24362326.
↑ ^14.0 ^14.1 ^14.2 ^14.3 ^14.4 Lund K, Adams PD, Copland M (2014). "EZH2 in normal and malignant hematopoiesis". Leukemia. 28 (1): 44–9. doi:10.1038/leu.2013.288. PMID 24097338.
↑ "RefSeq". RefSeq Gene EZH2. Retrieved February 1, 2015.
↑ ^16.0 ^16.1 ^16.2 ^16.3 ^16.4 ^16.5 ^16.6 Ding X, Wang X, Sontag S, Qin J, Wanek P, Lin Q, Zenke M (2014). "The polycomb protein Ezh2 impacts on induced pluripotent stem cell generation". Stem Cells Dev. 23 (9): 931–40. doi:10.1089/scd.2013.0267. PMC 3996971. PMID 24325319.
↑ ^17.0 ^17.1 ^17.2 ^17.3 ^17.4 ^17.5 ^17.6 O'Meara MM, Simon JA (2012). "Inner workings and regulatory inputs that control Polycomb repressive complex 2". Chromosoma. 121 (3): 221–34. doi:10.1007/s00412-012-0361-1. PMC 3351537. PMID 22349693.
↑ ^18.0 ^18.1 "Histone H3K27". EpiGenie.
↑ Grewal SI, Jia S (2007). "Heterochromatin revisited". Nat. Rev. Genet. 8 (1): 35–46. doi:10.1038/nrg2008. PMID 17173056.
↑ ^20.0 ^20.1 Stewart MD, Li J, Wong J (2005). "Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment". Mol. Cell. Biol. 25 (7): 2525–2538. doi:10.1128/MCB.25.7.2525-2538.2005. PMC 1061631. PMID 15767660.
↑ Jeanteur, Philippe (2008). Epigenetics and Chromatin. Springer.
↑ ^22.0 ^22.1 Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA, Reinberg D (2010). "Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA". Genes Dev. 24 (23): 2615–20. doi:10.1101/gad.1983810. PMC 2994035. PMID 21123648.
↑ Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A, Diaz MO, Scacheri PC, Harte PJ (2009). "CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing". Development. 136 (18): 3131–41. doi:10.1242/dev.037127. PMC 2730368. PMID 19700617.
↑ Cao R, Zhang Y (2004). "SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex". Mol. Cell. 15 (1): 57–67. doi:10.1016/j.molcel.2004.06.020. PMID 15225548.
↑ Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K (1998). "Point mutations in the WD40 domain of Eed block its interaction with Ezh2". Mol. Cell. Biol. 18 (10): 5634–42. PMC 109149. PMID 9742080.
↑ ^26.0 ^26.1 ^26.2 ^26.3 Grzenda A, Lomberk G, Svingen P, Mathison A, Calvo E, Iovanna J, Xiong Y, Faubion W, Urrutia R (February 28, 2013). "Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression". Epigenetics & Chromatin. 6 (1): 3. doi:10.1186/1756-8935-6-3. PMC 3606351. PMID 23448518.
↑ Martin C, Zhang Y (2005). "The diverse functions of histone lysine methylation". Nat. Rev. Mol. Cell Biol. 6 (11): 838–849. doi:10.1038/nrm1761. PMID 16261189.
↑ Brien GL, Gambero G, O'Connell DJ, Jerman E, Turner SA, Egan CM, et al. (2012). "Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation". Nat. Struct. Mol. Biol. 19 (12): 1273–1281. doi:10.1038/nsmb.2449. PMID 23160351.
↑ ^29.0 ^29.1 Dillon SC, Zhang X, Trievel RC, Cheng X (2005). "The SET-domain protein superfamily: protein lysine methyltransferases" (PDF). Genome Biol. 6 (8): 227. doi:10.1186/gb-2005-6-8-227. Retrieved February 1, 2015.
↑ ^30.0 ^30.1 ^30.2 ^30.3 Kipp DR, Quinn CM, Fortin PD (2013). "Enzyme-dependent lysine deprotonation in EZH2 catalysis". Biochemistry. 52 (39): 6866–78. doi:10.1021/bi400805w. PMID 24000826.
↑ ^31.0 ^31.1 "'Window of Vulnerability'". Harvard Medical School.
↑ ^32.0 ^32.1 Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, Roth BL, Brown PJ, Frye SV, Arrowsmith CH, Hahn KM, Wang GG, Vedadi M, Jin J (2013). "An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1". ACS Chem. Biol. 8 (6): 1324–34. doi:10.1021/cb400133j. PMC 3773059. PMID 23614352.
↑ Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003). "EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer". EMBO J. 22 (20): 5323–35. doi:10.1093/emboj/cdg542. PMC 213796. PMID 14532106.
↑ Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Zhang Y, Hong M, Shang Y (2007). "Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells". Mol. Cell. Biol. 27 (14): 5105–19. doi:10.1128/MCB.00162-07. PMC 1951944. PMID 17502350.
↑ Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. (2010). "Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin". Nat. Genet. 42 (2): 181–5. doi:10.1038/ng.518. PMC 2850970. PMID 20081860.
↑ ^36.0 ^36.1 Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q (2007). "Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells". Genes Dev. 21 (9): 1050–63. doi:10.1101/gad.1524107. PMC 1855231. PMID 17437993.
↑ ^37.0 ^37.1 Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. (2012). "A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells". Nat. Chem. Biol. 8 (11): 890–6. doi:10.1038/nchembio.1084. PMID 23023262.
↑ ^38.0 ^38.1 ^38.2 Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. (2012). "Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation". Proc. Natl. Acad. Sci. U.S.A. 109 (52): 21360–5. doi:10.1073/pnas.1210371110. PMC 3535655. PMID 23236167.
↑ ^39.0 ^39.1 McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. (2012). "EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations". Nature. 492 (7427): 108–12. doi:10.1038/nature11606. PMID 23051747.
↑ ^40.0 ^40.1 Couture JF, Hauk G, Thompson MJ, Blackburn GM, Trievel RC (2006). "Catalytic roles for carbon-oxygen hydrogen bonding in SET domain lysine methyltransferases". J. Biol. Chem. 281 (28): 19280–7. doi:10.1074/jbc.M602257200. PMID 16682405.
↑ Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium. (2014, October 1).
↑ Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, et al. (2010). "Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes". Nat. Genet. 42 (8): 665–7. doi:10.1038/ng.620. PMID 20601954.
↑ "Ensembl". Gene Tree EZH2. Retrieved February 19, 2015.
↑ Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, Pillus L, Jenuwein T (1997). "Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres". EMBO J. 16 (11): 3219–32. doi:10.1093/emboj/16.11.3219. PMC 1169939. PMID 9214638.
↑ "NCBI UniGene". Enhancer of zeste homolog 2 (Drosophila) (EZH2). Retrieved February 1, 2015.
↑ "GeneCards". Enhancer Of Zeste Homolog 2 (Drosophila). Retrieved February 1, 2015.
↑ "Ensembl". Gene Tree EZH2. Retrieved February 1, 2015.
↑ Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. (2014). "Ensembl 2014". Nucleic Acids Res. 42 (Database issue): D749–55. doi:10.1093/nar/gkt1196. PMC 3964975. PMID 24316576.

@@ Line 1: / Line 1: @@
-<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
+{{Infobox_gene}}
-{{PBB_Controls
+'''Enhancer of zeste homolog 2''' (EZH2) is a [[Histone methyltransferase|histone-lysine N-methyltransferase]] [[enzyme]] ([[EC 2.1.1.43]]) encoded by EZH2 [[gene]], that participates in [[histone methylation]] and, ultimately, [[Transcriptional regulation|transcriptional repression]].<ref name="Viré_2006">{{cite journal | vauthors = Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F | displayauthors = 6 | title = The Polycomb group protein EZH2 directly controls DNA methylation | journal = Nature | volume = 439 | issue = 7078 | pages = 871–4 | year = 2006 | pmid = 16357870 | doi = 10.1038/nature04431 }}</ref> EZH2 catalyzes the addition of [[methyl groups]] to [[histone H3]] at [[lysine]] 27,<ref name="pmid12351676">{{cite journal | vauthors = Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y | title = Role of histone H3 lysine 27 methylation in Polycomb-group silencing | journal = Science | volume = 298 | issue = 5595 | pages = 1039–43 | year = 2002 | pmid = 12351676 | doi = 10.1126/science.1076997 }}</ref> by using the [[Cofactor (biochemistry)|cofactor]] [[S-Adenosyl-L-methionine|S-adenosyl-L-methionine]]. Methylation activity of EZH2 facilitates [[heterochromatin]] formation thereby silences gene function.<ref name="Viré_2006" /> Remodeling of chromosomal [[heterochromatin]] by EZH2 is also required during cell mitosis.
-| update_page = yes
-| require_manual_inspection = no
+EZH2 is the functional enzymatic component of the '''Polycomb Repressive Complex 2''' ([[PRC2]]), which is responsible for healthy [[embryonic development]] through the [[epigenetic]] maintenance of genes responsible for regulating development and [[Cellular differentiation|differentiation]].<ref name="pmid20346678">{{cite journal | vauthors = Morey L, Helin K | title = Polycomb group protein-mediated repression of transcription | journal = Trends Biochem. Sci. | volume = 35 | issue = 6 | pages = 323–32 | year = 2010 | pmid = 20346678 | doi = 10.1016/j.tibs.2010.02.009 }}</ref> EZH2 is responsible for the methylation activity of PRC2, and the complex also contains proteins required for optimal function ([[EED (protein)|EED]], [[SUZ12]], [[JARID2]], [[AEBP2]], [[RBBP4|RbAp46/48]], and [[PHF1|PCL]]).<ref name="pmid21248841">{{cite journal | vauthors = Margueron R, Reinberg D | title = The Polycomb complex PRC2 and its mark in life | journal = Nature | volume = 469 | issue = 7330 | pages = 343–9 | year = 2011 | pmid = 21248841 | pmc = 3760771 | doi = 10.1038/nature09784 }}</ref>
-| update_protein_box = yes
-| update_summary = no
+Mutation or over-expression of EZH2 has been linked to many forms of cancer.<ref>{{cite journal |last=Kim |first=Kimberly |last2=Roberts |first2=Charles |date=18 December 2015 |title=Targeting EZH2 in cancer |url=http://www.nature.com/nm/journal/v22/n2/full/nm.4036.html |journal=[[Nature Medicine]]|doi=10.1038/nm.4036|access-date=15 February 2016 |volume=22 |pages=128–134}}</ref> EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is upregulated in multiple cancers including, but not limited to, breast,<ref name="Yoo_2012">{{cite journal | vauthors = Yoo KH, Hennighausen L | title = EZH2 methyltransferase and H3K27 methylation in breast cancer | journal = Int. J. Biol. Sci. | volume = 8 | issue = 1 | pages = 59–65 | year = 2012 | pmid = 22211105 | pmc = 3226033 | doi = 10.7150/ijbs.8.59}}</ref> [[Prostate cancer|prostate]],<ref name="pmid12374981">{{cite journal | vauthors = Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM | title = The polycomb group protein EZH2 is involved in progression of prostate cancer | journal = Nature | volume = 419 | issue = 6907 | pages = 624–9 | year = 2002 | pmid = 12374981 | doi = 10.1038/nature01075 | laysummary = http://www.scientificamerican.com/article/scientists-identify-gene-2002-10-10/ | laysource = Scientific American  }}</ref> [[melanoma]],<ref name="pmid25609585">{{cite journal | vauthors = Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, Shakhova O, Dummer R, Sommer L | displayauthors = 6 | title = The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors | journal = Nat Commun | volume = 6 | issue = | pages = 6051 | year = 2015 | pmid = 25609585 | doi = 10.1038/ncomms7051 | laysummary = http://medicalresearch.com/genetic-research/epigenetic-control-protein-allows-melanoma-cells-metatasize/10949/ | laysource = MedicalResearch.com }}</ref> and bladder cancer.<ref name="pmid16215315">{{cite journal | vauthors = Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caşkurlu T, Cakir OO, Ergenekon E | title = Increased expression of EZH2, a polycomb group protein, in bladder carcinoma | journal = Urol. Int. | volume = 75 | issue = 3 | pages = 252–7 | year = 2005 | pmid = 16215315 | doi = 10.1159/000087804 }}</ref> Mutations in the EZH2 gene are also associated with [[Weaver syndrome]], a rare [[Congenital disorder|congenital]] disorder,<ref name="Gibson_2012">{{cite journal | vauthors = Gibson WT, Hood RL, Zhan SH, Bulman DE, Fejes AP, Moore R, Mungall AJ, Eydoux P, Babul-Hirji R, An J, Marra MA, Chitayat D, Boycott KM, Weaver DD, Jones SJ | displayauthors = 6 | title = Mutations in EZH2 cause Weaver syndrome | journal = Am. J. Hum. Genet. | volume = 90 | issue = 1 | pages = 110–8 | year = 2012 | pmid = 22177091 | pmc = 3257956 | doi = 10.1016/j.ajhg.2011.11.018 }}</ref> and EZH2 is involved in causing [[Neurodegenerative disease|neurodegenerative]] symptoms in the nervous system disorder, [[ataxia telangiectasia]].<ref name="pmid24162653">{{cite journal | vauthors = Li J, Hart RP, Mallimo EM, Swerdel MR, Kusnecov AW, Herrup K | title = EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia | journal = Nat. Neurosci. | volume = 16 | issue = 12 | pages = 1745–53 | year = 2013 | pmid = 24162653 | pmc = 3965909 | doi = 10.1038/nn.3564 }}</ref>
-| update_citations = yes
+== Function ==
+{{enzyme
+| align = left
+| Name = Histone-lysine N-methyltransferase
+| EC_number = 2.1.1.43
+| CAS_number =
+| IUBMB_EC_number = 2/1/1/43
+| GO_code =
+| image =
+| width =
+| caption =
 }}
-<!-- The GNF_Protein_box is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
+EZH2 is the catalytic [[Protein subunit|subunit]] of the Polycomb Repressive Complex 2 (PRC2).<ref name="UniProt_Q15910">{{UniProt Full|Q15910}}</ref>  EZH2's catalytic activity relies on its formation of a complex with at least two other PRC2 components, [[SUZ12]] and [[EED (protein)|EED]].<ref name="Tan_2014" />  <br />
-{{GNF_Protein_box
+<br />
- | image =
+As a [[histone methyltransferase]] (HMTase), EZH2's primary function is to [[Methylation|methylate]] Lys-27 on [[histone 3]] (H3K27me) by transferring a methyl group from the cofactor S-adenosyl-L-methionine (SAM). EZH2 is capable of mono-, di-, and tri-[[methylation]] of H3K27 and has been associated with a variety of biological functions, including transcriptional regulation in [[hematopoiesis]], development, and [[cell differentiation]].<ref name="Tan_2014" /><ref name="Lund_2014" /><ref name=":4">{{Cite web|url = https://cgwb.nci.nih.gov/cgi-bin/hgc?hgsid=518648&c=chr7&o=148504463&t=148581441&g=refGene&i=NM_001203247|title = RefSeq|date = |accessdate = February 1, 2015|website = RefSeq Gene EZH2|publisher = }}</ref><ref name="Ding_2014">{{cite journal | vauthors = Ding X, Wang X, Sontag S, Qin J, Wanek P, Lin Q, Zenke M | title = The polycomb protein Ezh2 impacts on induced pluripotent stem cell generation | journal = Stem Cells Dev. | volume = 23 | issue = 9 | pages = 931–40 | year = 2014 | pmid = 24325319 | pmc = 3996971 | doi = 10.1089/scd.2013.0267 }}</ref>
- | image_source =
- | PDB =
+Recent studies have indicated that EZH2 is also capable of methylating non-[[histone]] proteins.<ref name="Tan_2014">{{cite journal | vauthors = Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE | title = EZH2: biology, disease, and structure-based drug discovery | journal = Acta Pharmacol. Sin. | volume = 35 | issue = 2 | pages = 161–74 | year = 2014 | pmid = 24362326 | pmc = 3914023 | doi = 10.1038/aps.2013.161 }}</ref><ref name="Lund_2014">{{cite journal | vauthors = Lund K, Adams PD, Copland M | title = EZH2 in normal and malignant hematopoiesis | journal = Leukemia | volume = 28 | issue = 1 | pages = 44–9 | year = 2014 | pmid = 24097338 | doi = 10.1038/leu.2013.288 }}</ref>
- | Name = Enhancer of zeste homolog 2 (Drosophila)
- | HGNCid = 3527
+=== Transcription repression ===
- | Symbol = EZH2
- | AltSymbols =; EZH1; ENX-1; MGC9169
+EZH2, as a part of PRC2, catalyzes trimethylation of H3K27 (H3K27me3), which is a histone modification that has been characterized as part of the [[histone code]].<ref name="UniProt_Q15910" /><ref name="Ding_2014" /><ref name="O'Meara_2012" /><ref name="EpiGenie">{{Cite web|url = http://epigenie.com/key-epigenetic-players/histone-proteins-and-modifications/histone-h3k27/ | title = Histone H3K27 |date = |work = EpiGenie }}</ref> The histone code is the theory that chemical modifications, such as [[methylation]], [[acetylation]], and [[ubiquitination]], of histone proteins play distinctive roles in [[epigenetic]] regulation of gene [[Transcription (genetics)|transcription]]. EZH2-mediated catalysis of H3K27me3 is associated with long term transcription repression.<ref name="UniProt_Q15910" /><ref name="Ding_2014" /><ref name="O'Meara_2012">{{cite journal | vauthors = O'Meara MM, Simon JA | title = Inner workings and regulatory inputs that control Polycomb repressive complex 2 | journal = Chromosoma | volume = 121 | issue = 3 | year = 2012 | pmid = 22349693 | doi = 10.1007/s00412-012-0361-1 | pages=221–34 | pmc=3351537}}</ref>
- | OMIM = 601573
- | ECnumber =
+EZH2, as well as other Polycomb group proteins, are involved in establishing and maintaining gene repression through [[cell division]].<ref name="Tan_2014" /><ref name="Ding_2014" /> This transcriptionally repressive state is thought to be due to PRC2/EZH2-EED-mediated H3K27 methylation and subsequent recruitment of [[PRC1]] which facilitates condensation of [[chromatin]] and formation of [[heterochromatin]].<ref name="Ding_2014" /> Heterochromatin is tightly packed chromatin which limits the accessibility of transcription machinery to the underlying DNA, thereby suppressing transcription.<ref name="pmid17173056">{{cite journal | vauthors = Grewal SI, Jia S | title = Heterochromatin revisited | journal = Nat. Rev. Genet. | volume = 8 | issue = 1 | pages = 35–46 | year = 2007 | pmid = 17173056 | doi = 10.1038/nrg2008 }}</ref>
- | Homologene = 37926
- | MGIid = 107940
+During cell division, heterochromatin formation is required for proper [[chromosome segregation]].<ref name="Stewart_2005">{{cite journal | vauthors = Stewart MD, Li J, Wong J | title = Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment | journal = Mol. Cell. Biol. | volume = 25 | issue = 7 | pages = 2525–2538 | year = 2005 | pmid = 15767660 | doi = 10.1128/MCB.25.7.2525-2538.2005 | pmc=1061631}}</ref> PRC2/EED-EZH2 complex may also be involved in the recruitment of DNA methyltransferases ([[DNMT]]<nowiki/>s), which results in increased [[DNA methylation]], another epigenetic layer of transcription repression.<ref name="UniProt_Q15910" /><ref name="Tan_2014" /> Specific genes that have been identified as targets of EZH2-mediated transcriptional repression include [[HOXA9]], [[HOXC8]], [[MYT1]], CDKN2A and [[retinoic acid]] target genes.<ref name="UniProt_Q15910" />
- | GeneAtlas_image1 = PBB_GE_EZH2_203358_s_at_tn.png
- | Function = {{GNF_GO|id=GO:0003677 |text = DNA binding}} {{GNF_GO|id=GO:0003682 |text = chromatin binding}} {{GNF_GO|id=GO:0005515 |text = protein binding}} {{GNF_GO|id=GO:0042054 |text = histone methyltransferase activity}}
+=== Transcription activation ===
-  | Component = {{GNF_GO|id=GO:0005634 |text = nucleus}} {{GNF_GO|id=GO:0035098 |text = ESC/E(Z) complex}} {{GNF_GO|id=GO:0045120 |text = pronucleus}}
+In cancer, EZH2 may play a role in activation of transcription, independently of [[PRC2]].<ref name="Tan_2014" /> In breast cancer cells, EZH2 has been demonstrated to activate [[NF-κB]] target genes, which are involved in responses to stimuli.<ref name="Tan_2014" /> The functional role of this activity and its mechanism are still unknown.
- | Process = {{GNF_GO|id=GO:0006325 |text = establishment and/or maintenance of chromatin architecture}} {{GNF_GO|id=GO:0006350 |text = transcription}} {{GNF_GO|id=GO:0006355 |text = regulation of transcription, DNA-dependent}} {{GNF_GO|id=GO:0016571 |text = histone methylation}} {{GNF_GO|id=GO:0051154 |text = negative regulation of striated muscle cell differentiation}}
- | Orthologs = {{GNF_Ortholog_box
+=== Development and cell differentiation ===
-    | Hs_EntrezGene = 2146
+EZH2 plays an essential role in development. In particular, it helps control transcriptional repression of genes that regulate cell differentiation.<ref name="Tan_2014" /><ref name="Lund_2014" /><ref name="Ding_2014" /><ref name="O'Meara_2012" /> In embryonic stem cells, EZH2-mediated trimethylation of H3K27me3 in regions containing developmental genes appears to be important for maintenance of normal cell differentiation.<ref name="Ding_2014" /> H3K27me3 is also important in driving [[X-inactivation]], the silencing of one [[X-chromosome]] in females during development.<ref name="EpiGenie" /> During X-inactivation, it is thought that EZH2 is involved in initiating heterochromatin formation by trimethylating H3K27 and that other [[histone methyltransferase]]<nowiki/>s and histone marks may be involved in maintaining the silenced state.<ref>{{cite book|title = Epigenetics and Chromatin|last = Jeanteur|first = Philippe|publisher = Springer|year = 2008|isbn = |pages = |url = https://books.google.com/books?id=GbTGDgApUM8C&pg=PA108&lpg=PA108&dq=x-inactivation+ezh2&source=bl&ots=5tqqg1tOSZ&sig=Ua6h5NBtXDrv1BDNVACTT798CNw&hl=en&sa=X&ei=xX_mVMe_OMO1sQSonYKgBg&ved=0CFQQ6AEwBw#v=onepage&q=x-inactivation%20ezh2&f=false}}</ref>
-    | Hs_Ensembl = ENSG00000106462
-    | Hs_RefseqProtein = NP_004447
+Further, EZH2 has been identified as an essential protein involved in development and differentiation of [[B-cells]] and [[T-cells]].<ref name="Lund_2014" /> H3K27me3 is involved in suppressing genes that promote differentiation, thus maintaining an undifferentiated state of B- and T-cells and playing an important role in regulating [[hematopoiesis]].<ref name="Lund_2014" />
-    | Hs_RefseqmRNA = NM_004456
-    | Hs_GenLoc_db =
+=== Regulation of EZH2 activity ===
-    | Hs_GenLoc_chr = 7
+The activity of EZH2 is regulated by the post-translational [[phosphorylation]] of [[threonine]] and [[serine]] residues on EZH2.<ref name="Kaneko_2010">{{cite journal | vauthors = Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA, Reinberg D | title = Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA | journal = Genes Dev. | volume = 24 | issue = 23 | pages = 2615–20 | year = 2010 | pmid = 21123648 | pmc = 2994035 | doi = 10.1101/gad.1983810 }}</ref> Specifically, [[phosphorylation]] of T350 has been linked to an increase in EZH2 activity while phosphorylation of T492 and S21 have been linked to a decrease in EZH2 activity.<ref name="O'Meara_2012" /><ref name="Kaneko_2010" /> Phosphorylation of T492 has been suggested to disrupt contacts between human EZH2 and its binding partners in the PRC2 complex, thus hindering its catalytic activity.<ref name="O'Meara_2012" />
-    | Hs_GenLoc_start = 148135408
-    | Hs_GenLoc_end = 148212347
+In addition to phosphorylation, it has also been shown that PRC2/EZH2-EED activity is antagonized by transcription-activating histone marks, such as [[acetylation]] of H3K27 ([[H3K27ac]]) and methylation of H3K36 ([[H3K36me]]).<ref name="O'Meara_2012" /><ref name="pmid19700617">{{cite journal | vauthors = Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A, Diaz MO, Scacheri PC, Harte PJ | title = CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing | journal = Development | volume = 136 | issue = 18 | pages = 3131–41 | year = 2009 | pmid = 19700617 | pmc = 2730368 | doi = 10.1242/dev.037127 }}</ref>
-    | Hs_Uniprot = Q15910
-    | Mm_EntrezGene = 14056
+== Enzymatic activity ==
-    | Mm_Ensembl = ENSMUSG00000029687
+EZH2 function is highly dependent upon its recruitment by the PRC2 complex. In particular, [[EED (protein)|WD40-repeat protein embryonic ectoderm development (EED)]] and [[SUZ12|zinc finger protein suppressor of zeste 12 (SUZ12)]] are needed to stabilize the interaction of EZH2 with its histone substrate<ref name="pmid15225548">{{cite journal | vauthors = Cao R, Zhang Y | title = SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex | journal = Mol. Cell | volume = 15 | issue = 1 | pages = 57–67 | year = 2004 | pmid = 15225548 | doi = 10.1016/j.molcel.2004.06.020 | url = }}</ref><ref name="pmid9742080">{{cite journal | vauthors = Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K | title = Point mutations in the WD40 domain of Eed block its interaction with Ezh2 | journal = Mol. Cell. Biol. | volume = 18 | issue = 10 | pages = 5634–42 | year = 1998 | pmid = 9742080 | pmc = 109149 | doi = | url = }}</ref> Recently, two isoforms of EZH2 generated from [[alternative splicing]] have been identified in humans: EZH2α and EZH2β.<ref name=":0">{{cite journal | vauthors = Grzenda A, Lomberk G, Svingen P, Mathison A, Calvo E, Iovanna J, Xiong Y, Faubion W, Urrutia R | title = Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression | journal = Epigenetics & Chromatin | volume = 6 | issue = 1 | date = February 28, 2013 | pmid =  23448518| doi = 10.1186/1756-8935-6-3 | pmc=3606351 | pages=3}}</ref> Both [[isoform]]s contain elements that have been identified as important for EZH2 function including the [[nuclear localization signal]], the EED and SUZ12 binding sites as well as the conserved SET domain.<ref name=":0" /> Most studies have thus far focused on the longer isoform EZH2α, but EZH2β, which lacks [[exon]]s 4 and 8, has been shown to be active.<ref name=":0" /> Furthermore, PRC2/EZH2β complexes act on distinct genes from that of its PRC2/EZH2α counterpart suggesting that each isoform may act to regulate a specific subset of genes.<ref name=":0" /> Additional evidence suggests that EZH2 may also be capable of lysine methylation independent of association with PRC2, when EZH2 is highly upregulated.<ref name="Tan_2014" />
-    | Mm_RefseqmRNA = NM_007971
-    | Mm_RefseqProtein = NP_031997
+===Lysine methylation===
-    | Mm_GenLoc_db =
+[[File:Lysgen.pdf|thumb|325px|Lysine can be methylated up to three times on its terminal ammonium group.]]
-    | Mm_GenLoc_chr = 6
+[[Methylation]] is the addition of a -CH<sub>3</sub>, or methyl group, to another molecule. In biology, methylation is typically catalyzed by enzymes, and methyl groups are commonly added to either proteins or nucleic acids. In EZH2-catalyzed methylation, the amino acid [[lysine]] in the histone h3 is methylated. This amino acid residue can be methylated up to three times on its terminal [[ammonium]] group. These methylated lysines are important in the control of mammalian gene expression and have a functional role in [[heterochromatin]] formation, [[X-inactivation|X-chromosome inactivation]] and transcriptional regulation.<ref>{{cite journal | vauthors = Martin C, Zhang Y | title = The diverse functions of histone lysine methylation | journal = Nat. Rev. Mol. Cell Biol. | volume = 6 | issue = 11 | pages = 838–849 | year = 2005 | pmid = 16261189 | doi = 10.1038/nrm1761 }}</ref> In mammalian chromosomes, histone lysine methylation can either activate or repress genes depending the site of methylation. Recent work has shown that at least part of the silencing function of the EZH2 complex is the methylation of [[histone H3]] on lysine 27.<ref>{{cite journal | vauthors = Brien GL, Gambero G, O'Connell DJ, Jerman E, Turner SA, Egan CM, Dunne EJ, Jurgens MC, Wynne K, Piao L, Lohan AJ, Ferguson N, Shi X, Sinha KM, Loftus BJ, Cagney G, Bracken AP | displayauthors = 6 | title = Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation | journal = Nat. Struct. Mol. Biol. | volume = 19 | issue = 12 | pages = 1273–1281 | year = 2012 | pmid = 23160351 | doi = 10.1038/nsmb.2449 }}</ref> Methylation, and other modifications, take place on the histones. Methyl modifications can affect the binding of proteins to these histones and either activate or inhibit [[Transcription (genetics)|transcription]].<ref name = "Stewart_2005"/>
-    | Mm_GenLoc_start = 47459867
-    | Mm_GenLoc_end = 47524606
+=== Mechanism of catalysis ===
-    | Mm_Uniprot = Q3TZH6
+[[File:EZH2 SET-domain.tiff|thumb|325px|STAMP Alignment of EZH2 (Yellow; PDB: 4MI0) and Human SET7/9 (Cyan; PDB:1O9S) SET Domains with SAM (red) and Lysine (blue) bound.]]
-  }}
+EZH2 is a member of the [[SET domain]] family of lysine [[methyltransferase]]s which function to add methyl groups to lysine side chains of [[Substrate (chemistry)|substrate]] proteins.<ref name="Trievel">{{cite journal | vauthors = Dillon SC, Zhang X, Trievel RC, Cheng X | title = The SET-domain protein superfamily: protein lysine methyltransferases | journal = Genome Biol. | volume = 6 | issue = 8 | year = 2005 | pmid =  | doi = 10.1186/gb-2005-6-8-227 | url = http://genomebiology.com/content/pdf/gb-2005-6-8-227.pdf | access-date = February 1, 2015 | pages=227}}</ref> SET methyltransferases depend on a S-Adenosyl methionine (SAM) cofactor to act as a methyl donor for their catalytic activity. SET domain proteins differ from other SAM-dependent [[methyltransferases]] in that they bind their substrate and SAM cofactor on opposite sides of the [[active site]] of the enzyme. This orientation of substrate and cofactor allows SAM to dissociate without disrupting substrate binding and can lead to multiple rounds of lysine methylation without substrate dissociation.<ref name="Trievel"/>
-}}
-'''Enhancer of zeste homolog 2 (Drosophila)''', also known as '''EZH2''', is a human [[gene]].
+Although neither a substrate-bound or SAM-bound crystal structure for EZH2 has been determined, STAMP structure alignment with the human SET7/9 methyltransferase shows conserved [[tyrosine]] residues in almost identical positions within the putative active site of EZH2.
+[[File:EZH2 active site residues.tiff|thumb|325px|STAMP Alignment of EZH2 (Yellow; PDB: 4MI0) and Human SET7/9 (Cyan; PDB:1O9S) Active Site Residues]]
+It had been previously suggested that tyrosine 726 in the EZH2 active site was acting as a general base to de-protonate the substrate lysine but kinetic isotope effects have indicated that active site residues are not directly involved in the chemistry of the methyltransferase reaction.<ref name="Kipp_2013">{{cite journal | vauthors = Kipp DR, Quinn CM, Fortin PD | title = Enzyme-dependent lysine deprotonation in EZH2 catalysis | journal = Biochemistry | volume = 52 | issue = 39 | pages = 6866–78 | year = 2013 | pmid = 24000826 | doi = 10.1021/bi400805w }}</ref> Instead these experiments support a mechanism in which the residues lower the [[pKa]] of the substrate lysine residue while simultaneously providing a channel for water to access the lysine side chain within the interior of the active site. Bulk solvent water can then easily [[deprotonate]] the lysine side chain, activating it for [[nucleophilic attack]] of the SAM cofactor in an [[SN2 reaction|S<sub>N</sub>2]]-like reaction resulting in transfer of the methyl group from SAM to the lysine side chain.<ref name="Kipp_2013"/>
+[[File:Lysine Methylation by SAM.tif|thumb|325px|Putative Catalytic Mechanism for EZH2]]
+EZH2 primarily catalyzes mono- and di-methylation of H3K27 but a clinically relevant mutation of residue tyrosine 641 to [[phenylalanine]] (Y641F) results in higher H3K27 tri-methylation activity.<ref name="Kipp_2013"/> It is proposed that the removal of the hydroxyl group on Y641 abrogates steric hindrance and allows for accommodation of a third methyl group on the substrate lysine. This EZH2 Y641F mutant is associated with many cancer phenotypes and implies that Y641 may be involved in regulating the number of methyl groups added to a single lysine residue.<ref name="Kipp_2013" />
+==Clinical significance==
+=== Cancer ===
+EZH2 is an attractive target for anti-cancer therapy because it helps cancerous cells divide and proliferate. It is found in larger amounts than in healthy cells in a wide range of cancers including breast, prostate, bladder, [[Uterine cancer|uterine]], and [[Renal Cancer|renal]] cancers, as well as [[melanoma]] and [[lymphoma]]. EZH2 is a [[gene]] suppressor, so when it becomes overexpressed, many tumor suppressor genes that are normally turned on, are turned off. Inhibition of EZH2 function shrinks [[malignant]] [[tumor]]s in some reported cases because those tumor suppressor genes are not silenced by EZH2.<ref name="url_HMS">{{cite web | url = http://hms.harvard.edu/news/window-vulnerability | title = 'Window of Vulnerability' | work = Harvard Medical School }}</ref> EZH2 typically is not expressed in healthy adults; it is only found in actively dividing cells, like those active during fetal development.<ref name="Konze_2013">{{cite journal | vauthors = Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, Roth BL, Brown PJ, Frye SV, Arrowsmith CH, Hahn KM, Wang GG, Vedadi M, Jin J | title = An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1 | journal = ACS Chem. Biol. | volume = 8 | issue = 6 | pages = 1324–34 | year = 2013 | pmid = 23614352 | pmc = 3773059 | doi = 10.1021/cb400133j }}</ref> Because of this characteristic, overexpression of EZH2 can be used as a diagnostic marker of cancer and some neurodegenerative disorders.<ref name="pmid24162653" /> However, there are cases where it is difficult to tell whether overexpression of EZH2 is the cause of a disease, or simply a consequence. If it is only a consequence, targeting EZH2 for inhibition may not cure the disease. One example of a cancer pathway in which EZH2 plays a role is the pRB-E2F pathway. It is downstream from the [[Retinoblastoma protein|pRB-E2F]] pathway, and signals from this pathway lead to EZH2 overexpression.<ref name="Bracken_2003">{{cite journal | vauthors = Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K | title = EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer | journal = EMBO J. | volume = 22 | issue = 20 | pages = 5323–35 | year = 2003 | pmid = 14532106 | pmc = 213796 | doi = 10.1093/emboj/cdg542 }}</ref> Another important characteristic of EZH2 is that when EZH2 is overexpressed, it can activate genes without forming [[PRC2]]. This is an issue because it means the methylation activity of the enzyme is not mediated by complex formation. In breast cancer cells, EZH2 activates genes that promote cell proliferation and survival.<ref name="Tan_2014" /> It can also activate regulatory genes like [[c-myc]] and [[cyclin D1]] by interacting with [[Wnt signaling pathway|Wnt signaling]] factors.<ref name="Shi_2007">{{cite journal | vauthors = Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Zhang Y, Hong M, Shang Y | title = Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells | journal = Mol. Cell. Biol. | volume = 27 | issue = 14 | pages = 5105–19 | year = 2007 | pmid = 17502350 | pmc = 1951944 | doi = 10.1128/MCB.00162-07 }}</ref> Importantly, the mutation of tyrosine 641 to phenylalanine in the active SET domain of EZH2 results in preference for H3K27 tri-methylation and has been linked to lymphoma.<ref name="pmid20081860">{{cite journal | vauthors = Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Schein J, Moore R, Holt R, Horsman DE, Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA | displayauthors = 6| title = Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin | journal = Nat. Genet. | volume = 42 | issue = 2 | pages = 181–5 | year = 2010 | pmid = 20081860 | pmc = 2850970 | doi = 10.1038/ng.518 }}</ref>
+[[File:EZH2 mechanism.pdf|thumb|325px|Schematic depicting the effects of overexpression of EZH2 and mutation of EZH2 on transcription.]]
+[[File:Methyltransferase EZH2 Inhibitor Chart.png|alt=EZH2 Inhibitors|thumb|325px|EZH2 Inhibitors.<sup>a </sup>;<ref name="pmid17437993">{{cite journal | vauthors = Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q | title = Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells | journal = Genes Dev. | volume = 21 | issue = 9 | pages = 1050–63 | year = 2007 | pmid = 17437993 | pmc = 1855231 | doi = 10.1101/gad.1524107 }}</ref> <sup>b </sup>;<ref name="pmid23023262">{{cite journal | vauthors = Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW | displayauthors = 6 | title = A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells | journal = Nat. Chem. Biol. | volume = 8 | issue = 11 | pages = 890–6 | year = 2012 | pmid = 23023262 | doi = 10.1038/nchembio.1084 }}</ref> <sup>c </sup>;<ref name="pmid23236167">{{cite journal | vauthors = Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, Zhang M, Zhou T, Feng G, Chen Z, Li G, Yang T, Zhao K, Liu X, Yu Z, Lu CX, Atadja P, Li E | displayauthors = 6 | title = Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 109 | issue = 52 | pages = 21360–5 | year = 2012 | pmid = 23236167 | pmc = 3535655 | doi = 10.1073/pnas.1210371110 }}</ref> <sup>d </sup>;<ref name="McCabe_2012">{{cite journal | vauthors = McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL | displayauthors = 6 | title = EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | journal = Nature | volume = 492 | issue = 7427 | pages = 108–12 | year = 2012 | pmid = 23051747 | doi = 10.1038/nature11606 }}</ref> <sup>e </sup>;<ref name="Konze_2013"/> <sup>f</sup><ref name="pmid16682405">{{cite journal | vauthors = Couture JF, Hauk G, Thompson MJ, Blackburn GM, Trievel RC | title = Catalytic roles for carbon-oxygen hydrogen bonding in SET domain lysine methyltransferases | journal = J. Biol. Chem. | volume = 281 | issue = 28 | pages = 19280–7 | year = 2006 | pmid = 16682405 | doi = 10.1074/jbc.M602257200 }}</ref>]]
+=== Inhibitors ===
+Developing an inhibitor of EZH2 and preventing unwanted histone methylation of tumor suppressor genes is a viable area of cancer research. EZH2 inhibitor development has focused on targeting the [[SET domain]] active site of the protein. Several inhibitors of EZH2 have been developed as of 2015, including [[3-Deazaneplanocin A|3-deazaneplanocin A]] (DZNep), EPZ005687, EI1, GSK126, and UNC1999. DZNep has potential antiviral and anti-cancer properties because it lowers EZH2 levels and induces [[apoptosis]] in breast and colon cancer cells.<ref name="pmid17437993"/> DZNep inhibits the hydrolysis of S-adenosyl-L-homocysteine (SAH), which is a product-based inhibitor of all protein methyltransferases, leading to increased cellular concentrations of SAH which in turn inhibits EZH2. However, DZNep is not specific to EZH2 and also inhibits other DNA methyltransferases.
+In 2012, a company called Epizyme revealed EPZ005687, an S-adenosylmethionine ([[S-adenosylmethionine synthetase enzyme|SAM]]) competitive inhibitor that is more selective than DZNep; it has a 50-fold increase in selectivity for EZH2 compared to [[EZH1]]. The drug blocks EZH2 activity by binding to the SET domain active site of the enzyme. EPZ005687 can also inhibit the Y641 and A677 mutants of EZH2, which may be applicable for treating non-Hodgkin's lymphoma.<ref name="pmid23023262"/> In 2013, Epizyme began Phase I clinical trials with another EZH2 inhibitor, tazemetostat (EPZ-6438), for patients with B-cell lymphoma.<ref>Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium. (2014, October 1).</ref>
+Sinefungin is another SAM-competitive inhibitor, however, like DZNep, it is not specific to EZH2.<ref name="pmid16682405"/> It works by binding in the cofactor binding pocket of DNA methyltransferases to block methyl transfer. EI1 is another inhibitor, developed by [[Novartis]], that showed EZH2 inhibitory activity in lymphoma tumor cells, including cells with the Y641 mutation.<ref name="pmid23236167"/> The mechanism of this inhibitor also involves competing with the SAM cofactor for binding to EZH2.<ref name="pmid23236167" /> GSK126 is a potent, SAM-competitive EZH2 inhibitor developed by [[GlaxoSmithKline]], that has 150-fold selectivity over EZH1 and a K<sub>i</sub> of 0.5-3 nM.<ref name="McCabe_2012"/> UNC1999 was developed as an analogue of GSK126, and was the first orally bioavailable EZH2 inhibitor to show activity. However, it is less selective than its counterpart GSK126, and it binds to EZH1 as well, increasing the potential for off-target effects.
+Combination therapies are being studied as possible treatments when primary treatments begin to fail. [[Etoposide]], a [[topoisomerase]] inhibitor, when combined with an EZH2 inhibitor, becomes more effective for non-small cell lung cancers with [[BRG1]] and [[Epidermal growth factor receptor|EGFR]] mutations.<ref name="url_HMS" /> However, EZH2 and lysine methylation can have tumor suppressing activity, for example in [[myelodysplastic syndrome]],<ref name="pmid20601954">{{cite journal | vauthors = Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH | displayauthors = 6 | title = Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes | journal = Nat. Genet. | volume = 42 | issue = 8 | pages = 665–7 | year = 2010 | pmid = 20601954 | doi = 10.1038/ng.620 }}</ref> indicating that EZH2 inhibition may not be beneficial in all cases.
+=== Weaver Syndrome ===
+Mutations in the EZH2 gene have been linked with [[Weaver syndrome]], a rare disorder characterized by advanced bone age, [[macrocephaly]], and [[hypertelorism]].<ref name="Gibson_2012" /> The [[histidine]] residue in the active site of the [[wild-type]] EZH2 was mutated to [[tyrosine]] in patients diagnosed with Weaver syndrome.<ref name="Gibson_2012" /> The mutation likely interferes with [[Cofactor (biochemistry)|cofactor]] binding and causes disruption of the natural function of the protein.<ref name="Gibson_2012" />
+== Taxonomic distribution ==
+[[File:EZH2 Gene Tree.png|thumb|Ensembl Gene Tree of homologs of EZH2.<ref>{{Cite web|url = http://www.ensembl.org/Homo_sapiens/Gene/Compara_Tree?db=core;g=ENSG00000106462;r=7:148807383-148884321;redirect=no|title = Ensembl|date = |accessdate = February 19, 2015|website = Gene Tree EZH2 }}</ref>  This gene tree was generated using the [[Ensembl|Ensembl database]], using all 587 genes for EZH2 and the species each gene is found in.|frame]]
+Enhancer of zeste (E(z)) was originally identified in [[Drosophila melanogaster]], and its mammalian homologs were subsequently identified and named [[EZH1]] (enhancer of zeste homolog 1) and EZH2 (enhancer of zeste homolog 2).<ref name="pmid9214638">{{cite journal | vauthors = Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, Pillus L, Jenuwein T | title = Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres | journal = EMBO J. | volume = 16 | issue = 11 | pages = 3219–32 | year = 1997 | pmid = 9214638 | pmc = 1169939 | doi = 10.1093/emboj/16.11.3219 }}</ref> EZH2 is highly conserved through [[evolution]]. It and its homologs play essential roles in development, cell differentiation, and cell division in plants, insects, fish, and mammals.<ref name="Tan_2014" /><ref name="O'Meara_2012" /><ref name=":7">{{Cite web|url = https://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=444082&ALLPROT=1|title = NCBI UniGene|date = |accessdate = February 1, 2015|website = Enhancer of zeste homolog 2 (Drosophila) (EZH2)|publisher =  }}</ref><ref name=":8">{{Cite web|url = http://www.genecards.org/cgi-bin/carddisp.pl?gene=EZH2&ortholog=all#orthologs|title = GeneCards|date = |accessdate = February 1, 2015|website = Enhancer Of Zeste Homolog 2 (Drosophila)|publisher = }}</ref> The following taxonomic tree is a depiction of EZH2's distribution throughout a wide variety of species.<ref>{{Cite web|url = http://Dec2014.archive.ensembl.org/Homo_sapiens/Gene/Compara_Tree?db=core;g=ENSG00000106462;r=7:148807383-148884321;redirect=no|title = Ensembl|date = |accessdate = February 1, 2015|website = Gene Tree EZH2 }}</ref><ref>{{cite journal | vauthors = Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Girón CG, Gordon L, Hourlier T, Hunt S, Johnson N, Juettemann T, Kähäri AK, Keenan S, Kulesha E, Martin FJ, Maurel T, McLaren WM, Murphy DN, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, Riat HS, Ruffier M, Sheppard D, Taylor K, Thormann A, Trevanion SJ, Vullo A, Wilder SP, Wilson M, Zadissa A, Aken BL, Birney E, Cunningham F, Harrow J, Herrero J, Hubbard TJ, Kinsella R, Muffato M, Parker A, Spudich G, Yates A, Zerbino DR, Searle SM | displayauthors = 6 | title = Ensembl 2014 | journal = Nucleic Acids Res. | volume = 42 | issue = Database issue | pages = D749–55 | year = 2014 | pmid = 24316576 | pmc = 3964975 | doi = 10.1093/nar/gkt1196 }}</ref>
+{{Clear}}
+==See also==
+* [[Ezh2 gene]]
-<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
+== References ==
-{{PBB_Summary
+{{Reflist|33em}}
-| section_title =
-| summary_text = This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the [[VAV1]] oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Two transcript variants encoding distinct isoforms have been identified for this gene.<ref name="entrez">{{cite web | title = Entrez Gene: EZH2 enhancer of zeste homolog 2 (Drosophila)| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=2146| accessdate = }}</ref>
-}}
-==References==
+== Further reading ==
-{{reflist|2}}
+{{refbegin|33em}}
-==Further reading==
+* {{cite journal | vauthors = Zeidler M, Kleer CG | title = The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer | journal = Journal of Molecular Histology | volume = 37 | issue = 5–7 | pages = 219–23 | date = Sep 2006 | pmid = 16855786 | doi = 10.1007/s10735-006-9042-9 }}
-{{refbegin | 2}}
+* {{cite journal | vauthors = De Haan G, Gerrits A | title = Epigenetic control of hematopoietic stem cell aging the case of Ezh2 | journal = Annals of the New York Academy of Sciences | volume = 1106 | issue = 1 | pages = 233–9  | date = Jun 2007 | pmid = 17332078 | doi = 10.1196/annals.1392.008 }}
-{{PBB_Further_reading
+* {{cite journal | vauthors = Hobert O, Jallal B, Ullrich A | title = Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression | journal = Molecular and Cellular Biology | volume = 16 | issue = 6 | pages = 3066–73  | date = Jun 1996 | pmid = 8649418 | pmc = 231301 | doi =  }}
-| citations =
+* {{cite journal | vauthors = Bonaldo MF, Lennon G, Soares MB | title = Normalization and subtraction: two approaches to facilitate gene discovery | journal = Genome Research | volume = 6 | issue = 9 | pages = 791–806 |  date = Sep 1996 | pmid = 8889548 | doi = 10.1101/gr.6.9.791 }}
-*{{cite journal  | author=Zeidler M, Kleer CG |title=The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. |journal=J. Mol. Histol. |volume=37 |issue= 5-7 |pages= 219-23 |year= 2007 |pmid= 16855786 |doi= 10.1007/s10735-006-9042-9 }}
+* {{cite journal | vauthors = Abel KJ, Brody LC, Valdes JM, Erdos MR, McKinley DR, Castilla LH, Merajver SD, Couch FJ, Friedman LS, Ostermeyer EA, Lynch ED, King MC, Welcsh PL, Osborne-Lawrence S, Spillman M, Bowcock AM, Collins FS, Weber BL | title = Characterization of EZH1, a human homolog of Drosophila Enhancer of zeste near BRCA1 | journal = Genomics | volume = 37 | issue = 2 | pages = 161–71 | date = Oct 1996 | pmid = 8921387 | doi = 10.1006/geno.1996.0537 }}
-*{{cite journal  | author=De Haan G, Gerrits A |title=Epigenetic control of hematopoietic stem cell aging the case of Ezh2. |journal=Ann. N. Y. Acad. Sci. |volume=1106 |issue=  |pages= 233-9 |year= 2007 |pmid= 17332078 |doi= 10.1196/annals.1392.008 }}
+* {{cite journal | vauthors = Laible G, Wolf A, Dorn R, Reuter G, Nislow C, Lebersorger A, Popkin D, Pillus L, Jenuwein T | title = Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres | journal = The EMBO Journal | volume = 16 | issue = 11 | pages = 3219–32  | date = Jun 1997 | pmid = 9214638 | pmc = 1169939 | doi = 10.1093/emboj/16.11.3219 }}
-*{{cite journal  | author=Hobert O, Jallal B, Ullrich A |title=Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. |journal=Mol. Cell. Biol. |volume=16 |issue= 6 |pages= 3066-73 |year= 1996 |pmid= 8649418 |doi=  }}
+* {{cite journal | vauthors = Cardoso C, Timsit S, Villard L, Khrestchatisky M, Fontès M, Colleaux L | title = Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein | journal = Human Molecular Genetics | volume = 7 | issue = 4 | pages = 679–84  | date = Apr 1998 | pmid = 9499421 | doi = 10.1093/hmg/7.4.679 }}
-*{{cite journal  | author=Bonaldo MF, Lennon G, Soares MB |title=Normalization and subtraction: two approaches to facilitate gene discovery. |journal=Genome Res. |volume=6 |issue= 9 |pages= 791-806 |year= 1997 |pmid= 8889548 |doi=  }}
+* {{cite journal | vauthors = van Lohuizen M, Tijms M, Voncken JW, Schumacher A, Magnuson T, Wientjens E | title = Interaction of mouse polycomb-group (Pc-G) proteins Enx1 and Enx2 with Eed: indication for separate Pc-G complexes | journal = Molecular and Cellular Biology | volume = 18 | issue = 6 | pages = 3572–9  | date = Jun 1998 | pmid = 9584197 | pmc = 108938 | doi =  }}
-*{{cite journal  | author=Abel KJ, Brody LC, Valdes JM, ''et al.'' |title=Characterization of EZH1, a human homolog of Drosophila Enhancer of zeste near BRCA1. |journal=Genomics |volume=37 |issue= 2 |pages= 161-71 |year= 1997 |pmid= 8921387 |doi= 10.1006/geno.1996.0537 }}
+* {{cite journal | vauthors = Sewalt RG, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, Satijn DP, Hendrix T, van Driel R, Otte AP | title = Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes | journal = Molecular and Cellular Biology | volume = 18 | issue = 6 | pages = 3586–95  | date = Jun 1998 | pmid = 9584199 | pmc = 108940 | doi =  10.1128/mcb.18.6.3586}}
-*{{cite journal  | author=Chen H, Rossier C, Antonarakis SE |title=Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. |journal=Genomics |volume=38 |issue= 1 |pages= 30-7 |year= 1997 |pmid= 8954776 |doi= 10.1006/geno.1996.0588 }}
+* {{cite journal | vauthors = Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K | title = Point mutations in the WD40 domain of Eed block its interaction with Ezh2 | journal = Molecular and Cellular Biology | volume = 18 | issue = 10 | pages = 5634–42  | date = Oct 1998 | pmid = 9742080 | pmc = 109149 | doi =  }}
-*{{cite journal  | author=Laible G, Wolf A, Dorn R, ''et al.'' |title=Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. |journal=EMBO J. |volume=16 |issue= 11 |pages= 3219-32 |year= 1997 |pmid= 9214638 |doi= 10.1093/emboj/16.11.3219 }}
+* {{cite journal | vauthors = van der Vlag J, Otte AP | title = Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation | journal = Nature Genetics | volume = 23 | issue = 4 | pages = 474–8  | date = Dec 1999 | pmid = 10581039 | doi = 10.1038/70602 }}
-*{{cite journal  | author=Cardoso C, Timsit S, Villard L, ''et al.'' |title=Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. |journal=Hum. Mol. Genet. |volume=7 |issue= 4 |pages= 679-84 |year= 1998 |pmid= 9499421 |doi=  }}
+* {{cite journal | vauthors = Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, Colleaux L | title = The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders | journal = European Journal of Human Genetics | volume = 8 | issue = 3 | pages = 174–80  | date = Mar 2000 | pmid = 10780782 | doi = 10.1038/sj.ejhg.5200439 }}
-*{{cite journal  | author=van Lohuizen M, Tijms M, Voncken JW, ''et al.'' |title=Interaction of mouse polycomb-group (Pc-G) proteins Enx1 and Enx2 with Eed: indication for separate Pc-G complexes. |journal=Mol. Cell. Biol. |volume=18 |issue= 6 |pages= 3572-9 |year= 1998 |pmid= 9584197 |doi=  }}
+* {{cite journal | vauthors = Raaphorst FM, Otte AP, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Meijer CJ | title = Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation | journal = Journal of Immunology | volume = 166 | issue = 10 | pages = 5925–34  | date = May 2001 | pmid = 11342607 | doi = 10.4049/jimmunol.166.10.5925 }}
-*{{cite journal  | author=Sewalt RG, van der Vlag J, Gunster MJ, ''et al.'' |title=Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. |journal=Mol. Cell. Biol. |volume=18 |issue= 6 |pages= 3586-95 |year= 1998 |pmid= 9584199 |doi=  }}
+* {{cite journal | vauthors = O'Connell S, Wang L, Robert S, Jones CA, Saint R, Jones RS | title = Polycomblike PHD fingers mediate conserved interaction with enhancer of zeste protein | journal = The Journal of Biological Chemistry | volume = 276 | issue = 46 | pages = 43065–73  | date = Nov 2001 | pmid = 11571280 | doi = 10.1074/jbc.M104294200 }}
-*{{cite journal  | author=Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K |title=Point mutations in the WD40 domain of Eed block its interaction with Ezh2. |journal=Mol. Cell. Biol. |volume=18 |issue= 10 |pages= 5634-42 |year= 1998 |pmid= 9742080 |doi=  }}
+* {{cite journal | vauthors = Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM | title = The polycomb group protein EZH2 is involved in progression of prostate cancer | journal = Nature | volume = 419 | issue = 6907 | pages = 624–9  | date = Oct 2002 | pmid = 12374981 | doi = 10.1038/nature01075 }}
-*{{cite journal  | author=van der Vlag J, Otte AP |title=Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. |journal=Nat. Genet. |volume=23 |issue= 4 |pages= 474-8 |year= 1999 |pmid= 10581039 |doi= 10.1038/70602 }}
+* {{cite journal | vauthors = Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM | title = EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 100 | issue = 20 | pages = 11606–11  | date = Sep 2003 | pmid = 14500907 | pmc = 208805 | doi = 10.1073/pnas.1933744100 }}
-*{{cite journal  | author=Cardoso C, Mignon C, Hetet G, ''et al.'' |title=The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. |journal=Eur. J. Hum. Genet. |volume=8 |issue= 3 |pages= 174-80 |year= 2000 |pmid= 10780782 |doi= 10.1038/sj.ejhg.5200439 }}
-*{{cite journal  | author=Raaphorst FM, Otte AP, van Kemenade FJ, ''et al.'' |title=Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. |journal=J. Immunol. |volume=166 |issue= 10 |pages= 5925-34 |year= 2001 |pmid= 11342607 |doi=  }}
-*{{cite journal  | author=O'Connell S, Wang L, Robert S, ''et al.'' |title=Polycomblike PHD fingers mediate conserved interaction with enhancer of zeste protein. |journal=J. Biol. Chem. |volume=276 |issue= 46 |pages= 43065-73 |year= 2001 |pmid= 11571280 |doi= 10.1074/jbc.M104294200 }}
-*{{cite journal  | author=Varambally S, Dhanasekaran SM, Zhou M, ''et al.'' |title=The polycomb group protein EZH2 is involved in progression of prostate cancer. |journal=Nature |volume=419 |issue= 6907 |pages= 624-9 |year= 2002 |pmid= 12374981 |doi= 10.1038/nature01075 }}
-*{{cite journal  | author=Strausberg RL, Feingold EA, Grouse LH, ''et al.'' |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899-903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899 }}
-*{{cite journal  | author=Scherer SW, Cheung J, MacDonald JR, ''et al.'' |title=Human chromosome 7: DNA sequence and biology. |journal=Science |volume=300 |issue= 5620 |pages= 767-72 |year= 2003 |pmid= 12690205 |doi= 10.1126/science.1083423 }}
-*{{cite journal  | author=Hillier LW, Fulton RS, Fulton LA, ''et al.'' |title=The DNA sequence of human chromosome 7. |journal=Nature |volume=424 |issue= 6945 |pages= 157-64 |year= 2003 |pmid= 12853948 |doi= 10.1038/nature01782 }}
-*{{cite journal  | author=Kleer CG, Cao Q, Varambally S, ''et al.'' |title=EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=100 |issue= 20 |pages= 11606-11 |year= 2003 |pmid= 14500907 |doi= 10.1073/pnas.1933744100 }}
-}}
 {{refend}}
-{{protein-stub}}
+{{Transcription}}
-{{WikiDoc Sources}}
+{{One carbon transferases}}
+{{Enzymes}}
+{{Portal bar|Molecular and Cellular Biology|border=no}}
+[[Category:EC 2.1.1]]

v t e Enzymes
Activity	Active site Binding site Catalytic triad Oxyanion hole Enzyme promiscuity Catalytically perfect enzyme Coenzyme Cofactor Enzyme catalysis
Regulation	Allosteric regulation Cooperativity Enzyme inhibitor Enzyme activator
Classification	EC number Enzyme superfamily Enzyme family List of enzymes
Kinetics	Enzyme kinetics Eadie–Hofstee diagram Hanes–Woolf plot Lineweaver–Burk plot Michaelis–Menten kinetics
Types	EC1 Oxidoreductases (list) EC2 Transferases (list) EC3 Hydrolases (list) EC4 Lyases (list) EC5 Isomerases (list) EC6 Ligases (list)